Peer-reviewed paper explains unprecedented performance of BioLargo’s AOS water treatment technology

This article will also be published as a press release on Monday, October 4, 2021. We released it on our blog today to help eager BioLargo followers understand the results of the paper. 

- BioLargo communications staff

Today BioLargo published an important peer-reviewed article confirming that its innovative water treatment technology, the Advanced Oxidation System (AOS), generates highly energetic iodine molecules. The article establishes the foundational scientific principles about why the AOS is a powerful, efficient, and novel water treatment technology.

The BioLargo AOS, which is currently deployed in a demonstration pilot project at a municipal wastewater treatment plant, is a ground-breaking water treatment platform that provides rapid and effective disinfection and concurrent organics removal while consuming less electricity than other common treatment technologies. The AOS has previously been shown in bench-scale and pilot-scale studies to exhibit greater water disinfection and decontamination performance than would be expected in similar water treatment technologies. This spurred BioLargo scientists and academic collaborators to elucidate the exact electrochemical mechanisms of the AOS in this study.

Graphical depiction of iodine spectroscopy results

The paper, published in the American Chemical Society’s journal ES&T Water, examines the mechanism by which the BioLargo AOS produces such rapid and effective disinfection performance relative to past electrochemical water treatment technologies. The study used the Canadian Light Source particle accelerator to perform advanced measurements of the chemical reactions that occur inside the AOS during operation. This technique revealed that the AOS generates highly oxidized iodine molecules that the researchers concluded are likely responsible for the technology’s elevated disinfection efficacy. These special iodine molecules were only present inside the active layers of the AOS and were neutralized before water flowed out of the AOS.

Dr. Richard Smith, President of BioLargo Water commented, “Our AOS technology is a technical leap forward in advanced water treatment. This study is integral in showing why the technology produces such high performance while consuming so little energy.”

Access the journal article in ACS EST&T Water here: https://pubs.acs.org/doi/full/10.1021/acsestwater.1c00149

Or read the free, open-source version published on ChemRxiv.org, here: https://chemrxiv.org/engage/chemrxiv/article-details/6102c081537d10350580560a

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo AOS Water Treatment Technology Montreal Pilot - Official Video

BioLargo's Advanced Oxidation System (AOS) water treatment technology is operating in a demonstration pilot near Montreal, in the province of Quebec. The pilot is being run and validated independently by water treatment technology experts from the world-renowned Centre des Technologies de l’Eau (CTE) in Montreal to record real-time data of AOS performance in a municipal wastewater stream. 

Watch this video to learn about why this pilot is so important and why the AOS is such a important new technology for the wastewater treatment industry.

To learn more about CTE, head to their website at https://cteau.com/

Or visit them on LinkedIn at https://www.linkedin.com/company/centre-des-technologies-de-l-eau/ 

BioLargo's Groundbreaking Technology to Eliminate the Presence of Forever Chemicals in Drinking Water

Source: Mark Gilman at Benzinga. To view the original article, go to https://www.benzinga.com/general/biotech/21/09/23049489/biolargos-groundbreaking-technology-to-eliminate-the-presence-of-forever-chemicals-in-drinking-wa

A bipartisan coalition of the U.S. House of Representatives in July helped pass the “PFAS Action Act of 2021,” which would establish a national drinking water standard for per- and polyfluoroalkyl substances (PFAS) contamination. The bill would enable the Environmental Protection Agency (EPA) to require the cleanup of sites found to be contaminated with two of the most common PFAS chemicals, PFOA and PFOS, set air emission rules surrounding the disposal and incineration of PFAS-laden waste, and place new limits on the introduction of PFAS chemicals into waterways.  

The movement on Capitol Hill also puts in the spotlight innovative companies like BioLargo, Inc. This cleantech company has developed groundbreaking technology that can economically and rapidly remove PFAS chemicals from water sources without producing large volumes of PFAS-laden waste, one of the principal drawbacks of common treatment solutions like carbon filtration.  

If the PFAS Action Act is passed by the Senate, select PFAS chemicals will be designated as hazardous materials, allowing the EPA to clean up contaminated sites and create stricter rules for handling them. Without making a mountain of PFAS-laden carbon waste associated with current technologies, the Westminster, California-based BioLargo’s Aqueous Electrostatic Concentrator (AEC) technology is proven to remove more than 99% of PFAS from contaminated water. Compared to carbon filtration systems, the AEC generates only a tiny fraction of the PFAS-laden waste and will cost less to operate. 

PFAS has become a major concern for the U.S. and other industrialized nations. The chemical has been found in the drinking water of more than 1,400 U.S. communities. It has been determined to be a top priority for cleanup because of its link to cancers, thyroid issues, fetal developmental problems, high cholesterol, and other medical disorders. PFAS has been found in contaminated industrial soil, landfills, airport groundwater, aquifers, municipal water sources, wells, and even lakes and streams. 

Concurrently, PFAS is unfortunately a familiar presence in homes, as they are used in the manufacture of many staple consumer items such as cleaning supplies, nonstick cookware, and packaging.   

Meanwhile, BioLargo has recently announced two new potential clients (a municipality in Southern California and a federal government agency). They recently sent the company PFAS-contaminated water samples to be treated by its AEC water treatment system. BioLargo sees this as an essential first step in its multi-phased commercial approach, which includes off-site treatment of client-supplied water, an on-site pilot treatment system at the client’s location, and ultimately, full-scale operations. 

“By treating client water with our in-house AEC system, we can optimize it for the unique characteristics of the water from each source and confirm for the client that our system removes PFAS to the levels that meet their particular regulatory requirements,” said Randall Moore, President of BioLargo’s engineering subsidiary. 

BioLargo is now preparing to build commercial-sized units for pilot projects to be used across the United States. The company is also aggressively pursuing potential markets in communities needing groundwater remediation near industrial sites, military bases, and airports.

For more information on BioLargo, go to www.biolargo.com, and to learn about their PFAS Testing Program, go to https://www.biolargoengineering.com/biolargo-pfas-testing-program/. 

For direct contact: Tonya Chandler, Director of Strategic Marketing and Business Development, tonya.chandler@biolargo.com 

Proactive Investors Interview: BioLargo says its PFAS water testing program has been met with 'impressive response' from customers

Source: Proactive Investors (https://ca.proactiveinvestors.com/companies/news/960057/biolargo-says-its-pfas-water-testing-program-has-been-met-with--impressive-response--from-customers-960057.html) 

BioLargo, Inc's Randy Moore and Tonya Chandler joined Proactive to speak about the group's new service testing customer water to detect per- and polyfluoroalkyl substances (PFAS) contamination levels.

The group say the program offers 'peace of mind and proof of concept' to customers who need PFAS water treatment solutions in the face of an uncertain and rapidly evolving technological and regulatory landscape. From there, BioLargo’s proprietary PFAS water treatment technology, the Aqueous Electrostatic Concentrator (AEC) is deployed.

BioLargo to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021

Westminster, CA – September 8, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The conference is being held virtually on September 13-15, 2021. 

President and CEO of BioLargo Dennis Calvert will present on the company's cleantech products and services, such as its newly launched PFAS Testing Program. Attendees will learn about BioLargo’s business strategy for becoming a major player in the emerging PFAS water treatment and remediation market.

Mr. Calvert’s presentation begins at 7:00 am Eastern Time on Monday, September 13, 2021, and will be available “on demand” for 90 days thereafter. 

You may register to view the presentation for no charge, at this link: https://journey.ct.events/view/8fc14545-db68-4397-90e6-45267377c156 

For additional information about the conference, visit www.hcwevents.com/annualconference. 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

BioLargo Launches PFAS Testing and Treatment System Selection Program

Westminster, CA – September 2, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it has launched a new service offering to test customer water to determine PFAS contamination levels and advise on appropriate treatment equipment options to meet federal, state and local regulatory requirements. The program offers peace of mind and proof of concept to customers who need PFAS water treatment solutions in the face of an uncertain and rapidly evolving technological and regulatory landscape.

Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that contaminate drinking water in thousands of sites in the United States. The Federal government, and many state governments, are tightening regulations due to mounting evidence about the impacts of PFAS chemicals on human health and their ubiquity in water throughout the developed world. Learn more at https://www.biolargoengineering.com/biolargo-answers-administrations-urgent-call-for-mitigation-of-pfas-forever-chemicals/.

BioLargo’s new PFAS Testing Program offers customers timely, accurate, and reliable testing of their water to determine, quantify, and qualify their PFAS contamination problem. Once contamination and water chemistry are characterized, BioLargo selects and optimizes appropriate water treatment equipment from a menu of different technologies that addresses the customer’s specific water chemistry and PFAS contamination makeup. The company then offers on-site piloting of the company’s own PFAS water treatment technology (the Aqueous Electrostatic Concentrator, or AEC). The AEC is a low-cost, low-waste, and sustainable solution for removing PFAS from water.

Customers can reach out to BioLargo engineers to schedule testing at https://www.biolargoengineering.com/biolargo-pfas-testing-program/.  

Randall Moore, President of BioLargo’s engineering division said, “With the launch of this new program, our engineers will be able to better serve municipalities that are struggling with having to close water wells due to PFAS contamination. Our AEC system reduces treatment costs because it generates only a fraction of the PFAS-laden waste compared to other treatment technologies like carbon filtration or ion exchange. No two water sources have the same underlying chemistry, and there are over 4,500 different PFAS compounds that can contaminate water. Thus, it is crucial to optimize treatment processes for each situation.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.